Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy

Summary: Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown. We investigated circulating NEPa and neprilysin protein concentrations in obesity, T2D...

Description complète

Détails bibliographiques

Auteurs principaux:	Sasha A.S. Kjeldsen, Lise L. Gluud, Mikkel P. Werge, Julie S. Pedersen, Flemming Bendtsen, Kleopatra Alexiadou, Tricia Tan, Signe S. Torekov, Eva W. Iepsen, Nicole J. Jensen, Michael M. Richter, Jens P. Goetze, Jørgen Rungby, Bolette Hartmann, Jens J. Holst, Birgitte Holst, Joachim Holt, Finn Gustafsson, Sten Madsbad, Maria S. Svane, Kirstine N. Bojsen-Møller, Nicolai J. Wewer Albrechtsen
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2023-11-01
Collection:	iScience
Sujets:	Health sciences Obesity medicine Diabetology
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2589004223022678
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!